Eulanca Y. Liu

Eulanca Y. Liu

Auto-generated profile, based on publicly available information

Eulanca Y. Liu

Department of Radiation Oncology, UCLA, 200 Medical Plaza Driveway, Ste B265, Los Angeles, CA 90095

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Radiology: Imaging Cancer
Verified
Journal Article
Closed access
EJErika Jank
Erika Jank
ELEulanca Y. Liu
Eulanca Y. Liu
WDWilliam Delery
William Delery
PBPeter Boyle
Peter Boyle
CMClaudia Roberta Miller
Claudia Roberta Miller
RSRicky Savjani
Ricky Savjani
This review serves as a key reference for researchers, physicists, and clinicians on recent developments, software tools, evaluation metrics, and strategies for thoracic image registration and respiratory motion management in oncology.

23 July 2025 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PCP Travis Courtney
P Travis Courtney
JCJesus E Juarez Casillas
Jesus E Juarez Casillas
ELEulanca Y Liu
Eulanca Y Liu
MSMyung-Shin Sim
Myung-Shin Sim
LCLydia W Chau
Lydia W Chau
RSRicky R Savjani
Ricky R Savjani
Background: Residual or recurrent cancer after surgery but prior to adjuvant therapy occurs in a proportion of patients with head and neck cancer and may warrant treatment changes. 18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) may help identify residual or recurrent disease but is not routinely obtained. We evaluated the relevance of postoperative FDG-PET/CT in this clinical context. Methods: This single-institution, retrospective study identified patients with head and neck cancer who underwent definitive surgery between January 1, 2013, and April 1, 2023, and received a postoperative FDG-PET/CT prior to adjuvant treatment. We measured the rates of management changes resulting from postoperative FDG-PET/CT findings and the association between having a postoperative FDG-PET/CT which resulted in a management change and oncologic outcomes with selected multivariable competing-risks and proportional hazards regressions. Results: Of 150 patients, sixty-six (44.0%) had a management change because of the postoperative FDG-PET/CT findings. Sixty-two (93.8%) had radiotherapy plan changes, 20 (30.3%) underwent additional diagnostic testing, 11 (16.7%) had systemic therapy added or changed, 3 (4.6%) underwent reresection, and 15 (10.0%) switched to palliative-intent treatment. Having a postoperative FDG-PET/CT which resulted in a management change was not significantly associated with cancer recurrence or overall survival (both p > .05). Conclusion(s): In patients with resected head and neck cancer, postoperative, pre-adjuvant therapy FDG-PET/CT can alter clinical management and may enable additional personalization of treatment. When practical to obtain without delaying treatment, postoperative FDG-PET/CT may have clinical utility though requires careful interpretation due to the risks of false positives.